Executive Board
The Executive Board has been established to assist the Chief Executive in leading The Institute of Cancer Research to achieve its strategic aims and objectives within the approved strategies and budgets and is responsible for formulating strategies, plans and budgets for approval by the Board of Trustees.
Professor Kristian Helin
Chief Executive and President
Professor Kevin Harrington
Head of Division – Radiotherapy and Imaging
Professor Clare Isacke
Dean of Academic and Research Affairs
Paul Norris
Chief Financial Officer
Jonathan Monk
Chief Information Officer
Professor Jonathon Pines
Head of Division – Cell and Molecular Biology
Dr Barbara Pittam
Chief Research and Academic Officer
Dr Olivia Rossanese
Head of Division – Cancer Therapeutics
Latest ICR News
Blood test could spare men with advanced prostate cancer from futile chemotherapy
New research has identified a way to predict resistance to a cancer drug commonly used to treat advanced prostate cancer.
ICR researchers to contribute to £13.7m brain tumour research consortium
The NIHR has announced a £13.7 million investment into research to develop new brain tumour treatments in the UK. The funding will establish the NIHR Brain Tumour Research Consortium – a national partnership uniting hospitals, universities, cancer centres and charities, along with patients. This is a coordinated UK-wide effort, which will involve the ICR's scientists, aims to transform brain cancer treatment.
New structural insights reveal molecular details of a key step in cell cycle control
In a major advance for molecular biology and cancer research, scientists have uncovered the molecular mechanisms that control a key step during the activation of cyclin-dependent kinases (CDKs) – the master regulators of cell division.
Mapping myeloma mutations: study reveals why some drugs fail and others still work
A new study has shown that small genetic changes in a key protein can determine whether myeloma cells resist or respond to treatment – findings that could help clinicians choose more effective therapies for patients with this type of blood cancer.